Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Payables (2016 - 2025)

Agios Pharmaceuticals (AGIO) has disclosed Payables for 13 consecutive years, with $18.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Payables rose 10.29% year-over-year to $18.4 million, compared with a TTM value of $18.4 million through Dec 2025, up 10.29%, and an annual FY2025 reading of $18.4 million, up 10.29% over the prior year.
  • Payables was $18.4 million for Q4 2025 at Agios Pharmaceuticals, down from $19.6 million in the prior quarter.
  • Across five years, Payables topped out at $19.6 million in Q3 2025 and bottomed at $7.7 million in Q2 2021.
  • Average Payables over 5 years is $13.3 million, with a median of $12.4 million recorded in 2023.
  • The sharpest move saw Payables plummeted 50.49% in 2021, then surged 74.71% in 2025.
  • Year by year, Payables stood at $16.7 million in 2021, then increased by 11.47% to $18.6 million in 2022, then crashed by 47.46% to $9.8 million in 2023, then skyrocketed by 70.17% to $16.6 million in 2024, then grew by 10.29% to $18.4 million in 2025.
  • Business Quant data shows Payables for AGIO at $18.4 million in Q4 2025, $19.6 million in Q3 2025, and $17.5 million in Q2 2025.